These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 9387950

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
    Rahaghi FF, Miravitlles M.
    Respir Res; 2017 May 30; 18(1):105. PubMed ID: 28558837
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
    Sorrells S, Camprubi S, Griffin R, Chen J, Ayguasanosa J.
    Respir Med; 2015 Apr 30; 109(4):490-9. PubMed ID: 25727857
    [Abstract] [Full Text] [Related]

  • 25. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency.
    Schmid ST, Koepke J, Dresel M, Hattesohl A, Frenzel E, Perez J, Lomas DA, Miranda E, Greulich T, Noeske S, Wencker M, Teschler H, Vogelmeier C, Janciauskiene S, Koczulla AR.
    Int J Chron Obstruct Pulmon Dis; 2012 Apr 30; 7():687-96. PubMed ID: 23055718
    [Abstract] [Full Text] [Related]

  • 26. Alpha-1 Antitrypsin Augmentation Therapy Improves Survival in Severely Deficient Patients with Predicted FEV1 Between 10% and 60%: A Retrospective Analysis of the NHLBI Alpha-1 Antitrypsin Deficiency Registry.
    Rahaghi FF, Monk R, Ramakrishnan V, Beiko T, Strange C.
    Int J Chron Obstruct Pulmon Dis; 2020 Apr 30; 15():3193-3199. PubMed ID: 33299307
    [Abstract] [Full Text] [Related]

  • 27. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?
    Stockley RA, Edgar RG, Pillai A, Turner AM.
    Int J Chron Obstruct Pulmon Dis; 2016 Apr 30; 11():1745-56. PubMed ID: 27536086
    [Abstract] [Full Text] [Related]

  • 28. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency.
    Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Stockley RA.
    Eur Respir J; 2009 Jun 30; 33(6):1345-53. PubMed ID: 19196813
    [Abstract] [Full Text] [Related]

  • 29. Inhalation of [123I]alpha1-protease inhibitor: toward a new therapeutic concept of alpha1-protease inhibitor deficiency?
    Kropp J, Wencker M, Hotze A, Banik N, Hübner GE, Wunderlich G, Ulbrich E, Konietzko N, Biersack HJ.
    J Nucl Med; 2001 May 30; 42(5):744-51. PubMed ID: 11337570
    [Abstract] [Full Text] [Related]

  • 30. Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK).
    Campos MA, Kueppers F, Stocks JM, Strange C, Chen J, Griffin R, Wang-Smith L, Brantly ML.
    COPD; 2013 Dec 30; 10(6):687-95. PubMed ID: 23862647
    [Abstract] [Full Text] [Related]

  • 31. ICS Use May Modify FEV1 Decline in α1-Antitrypsin Deficiency Patients with Relatively High Blood Eosinophils.
    Low EV, Hughes SM, Zaffarullah S, Kantas D, Stockley RA, Turner AM.
    Respiration; 2018 Dec 30; 95(2):114-121. PubMed ID: 29253843
    [Abstract] [Full Text] [Related]

  • 32. Clinical features and prognosis of life time non-smokers with severe alpha 1-antitrypsin deficiency.
    Seersholm N, Kok-Jensen A.
    Thorax; 1998 Apr 30; 53(4):265-8. PubMed ID: 9741368
    [Abstract] [Full Text] [Related]

  • 33. Augmentation therapy with alpha1-antitrypsin: patterns of use and adverse events.
    Stoller JK, Fallat R, Schluchter MD, O'Brien RG, Connor JT, Gross N, O'Neil K, Sandhaus R, Crystal RG.
    Chest; 2003 May 30; 123(5):1425-34. PubMed ID: 12740257
    [Abstract] [Full Text] [Related]

  • 34. Heart rate variability reflects severity of COPD in PiZ alpha1-antitrypsin deficiency.
    Stein PK, Nelson P, Rottman JN, Howard D, Ward SM, Kleiger RE, Senior RM.
    Chest; 1998 Feb 30; 113(2):327-33. PubMed ID: 9498947
    [Abstract] [Full Text] [Related]

  • 35. Decline in FEV1 in patients with PiZ alpha-1-antitrypsin deficiency: the Australian experience.
    Burdon JG, Brenton S, Hocking V, Knight KR, Ayad M, Cook L, Janus ED.
    Respirology; 2002 Mar 30; 7(1):51-5. PubMed ID: 11896901
    [Abstract] [Full Text] [Related]

  • 36. Asthma features in severe alpha1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry.
    Eden E, Hammel J, Rouhani FN, Brantly ML, Barker AF, Buist AS, Fallat RJ, Stoller JK, Crystal RG, Turino GM.
    Chest; 2003 Mar 30; 123(3):765-71. PubMed ID: 12628876
    [Abstract] [Full Text] [Related]

  • 37. Alpha-1-antitrypsin replacement therapy: current status.
    Abusriwil H, Stockley RA.
    Curr Opin Pulm Med; 2006 Mar 30; 12(2):125-31. PubMed ID: 16456382
    [Abstract] [Full Text] [Related]

  • 38. [Augmentation therapy with human alpha 1-protease inhibitor: whom to treat when?].
    Wencker M.
    Med Klin (Munich); 1999 Mar 15; 94(3):137-9. PubMed ID: 10218347
    [Abstract] [Full Text] [Related]

  • 39. Alpha 1 antitrypsin to treat lung disease in alpha 1 antitrypsin deficiency: recent developments and clinical implications.
    Chapman KR, Chorostowska-Wynimko J, Koczulla AR, Ferrarotti I, McElvaney NG.
    Int J Chron Obstruct Pulmon Dis; 2018 Mar 15; 13():419-432. PubMed ID: 29430176
    [Abstract] [Full Text] [Related]

  • 40. Alpha1-antitrypsin deficiency.
    Gøtzsche PC, Johansen HK.
    N Engl J Med; 2009 Nov 19; 361(21):2101-2; author reply 2102. PubMed ID: 19923584
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.